HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis

@article{May2006HIVTR,
  title={HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis},
  author={Margaret T. May and Jonathan A. C. Sterne and Dominique Costagliola and Caroline A. Sabin and Andrew N Phillips and Amy C. Justice and François Dabis and John M. Gill and Jens D. Lundgren and Robert S. Hogg and Frank de Wolf and Gerd F{\"a}tkenheuer and Schlomo Staszewski and Antonella d’Arminio Monforte and Matthias Egger},
  journal={The Lancet},
  year={2006},
  volume={368},
  pages={451-458}
}
BACKGROUND Highly active antiretroviral therapy (HAART) for the treatment of HIV infection was introduced a decade ago. We aimed to examine trends in the characteristics of patients starting HAART in Europe and North America, and their treatment response and short-term prognosis. METHODS We analysed data from 22,217 treatment-naive HIV-1-infected adults who had started HAART and were followed up in one of 12 cohort studies. The probability of reaching 500 or less HIV-1 RNA copies per mL by 6… 
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies
TLDR
Estimating the prognosis over 5 years of HIV-1-infected, treatment-naive patients starting HAART, taking into account the immunological and virological response to therapy, found prognostic models with high discriminatory power over 5 Years were developed for patients startingHAART in industrialized countries.
Recent Trends in Early Stage Response to Combination Antiretroviral Therapy in Australia
TLDR
There have been incremental improvements for patients initiated on cART, as measured by overall response (viral load and CD4(+) T-cell count) and also increased durability of first-line ART regimens across the five time-periods examined.
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
  • Adam Margaret T Jorg-Janne Niels M John Heidi M Christo Trickey May Vehreschild Obel Gill Crane Boesecke P, A. Trickey, +21 authors J. Sterne
  • Medicine
    The lancet. HIV
  • 2017
TLDR
Even in the late ART era, survival during the first 3 years of ART continues to improve, which probably reflects transition to less toxic antiretroviral drugs, improved adherence, prophylactic measures, and management of comorbidity.
Effectiveness of highly active antiretroviral therapy (HAART) among HIV-infected patients in Mexico.
TLDR
Implementation of NGP for HAART access in a specialized care setting in Mexico resulted in an excellent virologic response, and younger age was a significant risk factor for VF.
Durability of Antiretroviral Therapy Regimens and Determinants for Change in HIV-1-Infected Patients in the TREAT Asia HIV Observational Database (TAHOD-LITE)
TLDR
Lower CD4+ T-cell count and the use of suboptimal regimens were important factors associated with higher risk of treatment switch and the rates of discontinuation of first- and second-line regimens have decreased over the last decade in Asia.
Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).
TLDR
The Antiretroviral Therapy Cohort Collaboration of HIV cohort studies in Europe and North America was established in 2000, with the aim of studying the prognosis for clinical events in acquired immune deficiency syndrome (AIDS) and the mortality of adult patients treated for HIV-1 infection.
Factors associated with different responses to combination antiretroviral therapy in an observational cohort study of HIV-1 infected patients
TLDR
Investigation into virological response to first-line cART across geographical regions found evidence of variation, which was most apparent in early-cART years, especially in East Europe.
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.
TLDR
In industrialized countries, the mortality experience of HIV-infected patients who start ART and survive the first 6 months continues to be higher than in the general population, but for many patients excess mortality is moderate and comparable with patients having other chronic conditions.
IMPACT OF ANTIRETROVIRAL THERAPY ON SURVIVAL IN HIV INFECTED PATIENTS
The main objective of the study is to compare the survival time on antiretroviral treated HIV patients (TG) versus untreated group (NTG). Medical records of confi rmed HIV patients between 1990 -2008
Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy
TLDR
Observed mortality remained fairly constant by duration of cART and was modelled accurately by accepted prognostic factors, and changes in mortality with age were similar to those in the Australian general population.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
TLDR
The CD4 cell count at initiation was the dominant prognostic factor in patients starting HAART, and should be taken into account in future treatment guidelines.
Changing patterns of mortality across Europe in patients infected with HIV-1
TLDR
Death rates across Europe among patients infected with HIV-1 have been falling since September, 1995, and at the beginning of 1998 were less than a fifth of their previous level.
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study
TLDR
The introduction of antiretroviral combination therapies outside the selected patient groups included in clinical trials has led to comparable reductions in disease progression and mortality in Switzerland.
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
TLDR
The initial drop in mortality and morbidity after the introduction of HAART has been sustained and potential long-term adverse effects associated with HAART have not altered its effectiveness in treating AIDS.
Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group.
  • J. Lundgren, A. Phillips, +10 authors C. Pedersen
  • Medicine
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association
  • 1997
TLDR
ARV therapy was more frequently used among patients from southern and central Europe as compared with patients from northern Europe, especially among patients with CD4 counts >200 cells/microl, and antifungal therapies are used differently in different parts of Europe.
Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.
  • R. Hogg, B. Yip, +4 authors J. Montaner
  • Medicine
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • 1999
TLDR
This population-based cohort study confirms that patients initially treated with a triple-drug antiretroviral regimen comprising 2 NRTIs plus protease inhibitor or a non-NRTI have a lower risk of morbidity and death than patients treated exclusively with 2 N RTIs.
Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers
TLDR
While mortality rates among HIV-infected individuals at the Royal Free Hospital, London have fallen since 1988, the deaths that do now occur are more diverse and are the result of a number of factors, including late presentation, delayed uptake of HAART and the previous use of treatment combinations that are now viewed as suboptimal.
Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy
TLDR
Clinical outcomes are reported in a large cohort of patients in France 24 months after initiation of triple therapy that contained protease inhibitors, according to virologic and immunologic response at 6 months, and the long-term prognosis of patients exhibiting such discordant responses remains unknown.
Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
TLDR
Over a 7-year period of CART use in clinical practice, risk of initial virological failure of treatment has halved at least, and data suggest the trend is due to improvements in CART regimens and greater effectiveness of their use.
Changing incidence of AIDS‐defining illnesses in the era of antiretroviral combination therapy
TLDR
The incidence of AIDS-defining events in patients with advanced HIV infection at Frankfurt University Hospital has declined by more than 70% from 1992 to 1996, with a trend for malignancies and single opportunistic infections, with the exception of mycobacterial diseases.
...
1
2
3
4
5
...